Penetration of aztreonam into human cerebrospinal fluid in the presence of meningeal inflammation.

R. L. Greenman, S. M. Arcey, G. M. Dickinson, J. E. Mokhbat, L. D. Sabath, T. B. Platt, L. T. Friedhoff

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Cerebrospinal fluid of aztreonam were measured in 11 patients with meningeal inflammation. Two to eight hours after a single 2 gm intravenous dose, CSF aztreonam levels ranged from 0.76 to 16.6 mg/l. The mean CSF concentration in four patients with viral meningitis was 1.28 mg/l, which was lower than the mean concentration of 7.2 mg/l in the five with bacterial, cryptococcal or carcinomatous meningitis. Two patients with infected subdural drains were also sampled serially and had CSF levels greater than 1 mg/l between 1 and 8 h post dose. Penetration of aztreonam into the CSF in the presence of meningeal inflammation appears adequate to warrant therapeutic trials in patients infected with susceptible organisms.
Original languageUndefined/Unknown
Pages (from-to)637-640
Number of pages4
JournalJournal of Antimicrobial Chemotherapy
Issue number5
StatePublished - 1985


  • Adult
  • Aged
  • Anti-Bacterial Agents/cf [Cerebrospinal Fluid]
  • Aztreonam
  • Female
  • Humans
  • Male
  • Meningitis/cf [Cerebrospinal Fluid]
  • Meningitis/dt [Drug Therapy]
  • Meningitis, Meningococcal/cf [Cerebrospinal Fluid]
  • Meningitis, Viral/cf [Cerebrospinal Fluid]
  • Middle Aged

Cite this